• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

How Second-Line Injectable Drugs Work.

作者信息

Van Deun Armand, Decroo Tom

机构信息

Independent Consultant, Leuven, Belgium.

Institute of Tropical Medicine, Unit of HIV and TB, Department of Clinical Sciences, Antwerp, Belgium.

出版信息

Clin Infect Dis. 2021 Jun 15;72(12):e1167-e1168. doi: 10.1093/cid/ciaa1874.

DOI:10.1093/cid/ciaa1874
PMID:33341871
Abstract
摘要

相似文献

1
How Second-Line Injectable Drugs Work.二线注射药物的作用机制。
Clin Infect Dis. 2021 Jun 15;72(12):e1167-e1168. doi: 10.1093/cid/ciaa1874.
2
Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.法国耐多药结核分枝杆菌临床分离株对二线注射用药物耐药性的分子研究
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01299-16. Print 2017 Feb.
3
Role of second-line injectable antituberculosis drugs in the treatment of MDR/XDR tuberculosis.二线注射用抗结核药物在耐多药/广泛耐药结核病治疗中的作用。
Int J Antimicrob Agents. 2017 Aug;50(2):252-254. doi: 10.1016/j.ijantimicag.2017.01.042. Epub 2017 Jun 5.
4
Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis.韩国耐多药结核病患者分枝杆菌分离株中与氨基糖苷类和卷曲霉素耐药及交叉耐药相关的多态性。
J Clin Microbiol. 2010 Feb;48(2):402-11. doi: 10.1128/JCM.01476-09. Epub 2009 Dec 23.
5
Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China.中国耐卡那霉素、阿米卡星和卷曲霉素的耐多药结核分枝杆菌分离株的分子和表型特征
Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):1959-66. doi: 10.1007/s10096-014-2144-5. Epub 2014 Jun 7.
6
Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains.用于检测耐多药结核分枝杆菌复合群菌株对二线药物耐药性的GenoType MTBDRsl检测新版本（v2.0）的性能
J Clin Microbiol. 2016 Jun;54(6):1573-1580. doi: 10.1128/JCM.00051-16. Epub 2016 Apr 6.
7
High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene.格鲁吉亚结核分枝杆菌分离株中卡那霉素、阿米卡星和卷曲霉素之间高水平的交叉耐药性与 rrs 基因突变密切相关。
Antimicrob Agents Chemother. 2009 Dec;53(12):5064-8. doi: 10.1128/AAC.00851-09. Epub 2009 Sep 14.
8
Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.在埃塞俄比亚接受耐多药结核病治疗的患者中，注射用二线抗结核药物的肾毒性和耳毒性症状：一项回顾性队列研究。
BMC Pharmacol Toxicol. 2019 May 23;20(1):31. doi: 10.1186/s40360-019-0313-y.
9
The safety and tolerability of the second-line injectable antituberculosis drugs in children.二线注射用抗结核药物在儿童中的安全性和耐受性。
Expert Opin Drug Saf. 2016 Nov;15(11):1491-1500. doi: 10.1080/14740338.2016.1223623. Epub 2016 Aug 22.
10
Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.利奈唑胺与二线抗结核药物对耐多药结核分枝杆菌的体内外相互作用
Int J Infect Dis. 2016 Nov;52:23-28. doi: 10.1016/j.ijid.2016.08.027. Epub 2016 Sep 7.

引用本文的文献

1
Evaluation of MeltPro Assay in Identification of Second-Line Injectable Drug Resistance in Multidrug-Resistant Tuberculosis Isolates.MeltPro检测法在多重耐药结核分枝杆菌分离株二线注射用药物耐药性鉴定中的评估
Infect Drug Resist. 2024 May 24;17:2069-2076. doi: 10.2147/IDR.S459142. eCollection 2024.
2
Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment.更新定义抗结核药物敏感性和耐药性的方法：对诊断和治疗的影响。
Eur Respir J. 2022 Apr 14;59(4). doi: 10.1183/13993003.00166-2022. Print 2022 Apr.